NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer
December 20, 2023 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that...
NeurAxis Reports Third Quarter 2023 Financial Results
November 20, 2023 17:30 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that...
NeurAxis Announces CareFirst BCBS Policy Coverage
November 15, 2023 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Secures $3 Million Financing
November 14, 2023 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device
November 08, 2023 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 08, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders
September 26, 2023 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that...
NeurAxis Reports Second Quarter 2023 Financial Results
September 21, 2023 08:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that...
NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase
September 13, 2023 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 13, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that...
NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS
September 12, 2023 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that...
NeurAxis Highlights Pediatric Post-Concussion Clinical Study
August 29, 2023 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that...